Physician profile
Syed Asad
NPI 1265448062
$10,234.47
in general payments reported to CMS, 2019-2025
47 companies · $711 in 2025
The $711 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,964 · 2020: $1,308 · 2021: $1,556 · 2022: $1,579 · 2023: $1,596 · 2024: $1,521 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,815 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,814.57 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,652.92 | 2019-2024 | |
| Abbvie INC. | $1,251.35 | 2019-2025 | Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,005.72 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $974.49 | 2019-2025 | Briviact |
| Biogen, INC. | $554.42 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Sunovion Pharmaceuticals INC. | $475.87 | 2019-2022 | |
| Amgen INC. | $384.10 | 2019-2025 | Uplizna |
| Sumitomo Pharma America, INC. | $382.12 | 2023-2024 | Aptiom |
| Allergan, INC. | $365.15 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $288.36 | 2022-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $274.10 | 2019-2020 | |
| Lundbeck LLC | $253.37 | 2022-2025 | Vyepti |
| Lilly USA, LLC | $184.09 | 2019-2024 | Reyvow, Emgality, Amyvid |
| Mallinckrodt Hospital Products INC. | $169.34 | 2021-2025 | Acthar |
| Biohaven Pharmaceuticals, INC. | $166.71 | 2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Asad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.